Nyrada (ASX:NYR) has begun recruiting participants for the phase Ia clinical trial for the company's lead drug candidate, NYR-BI03, according to a Monday filing with the Australian bourse.
NYR-BI03 is a small molecule, first-in-class neuroprotection, and cardioprotection treatment. The trial will be a double-blind, randomized, placebo-controlled, dose-escalating study, comprising five cohorts of eight participants, the filing stated.
First participant dosing is expected before the end of March, while final phase Ia trial readouts are likely in the third quarter of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.